Skip to main content
SpringerLink
Log in

Differential regulation of cell survival by CD40

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

The CD40 cell surface receptor is required for normal function of the immune system and is a positive regulator of cell survival for normal B-lymphocytes. However, there is evidence to support both pro- and anti-apoptotic functions for CD40 in malignant B-cells and epithelial cancers. There is increasing interest in the potential of CD40 activating agents as novel therapies for cancer and it is essential to understand the differential response of malignant cells, to inform the design of trials. Here we review the current understanding of differential responses to CD40 activation and apoptosis controlling proteins regulated by CD40 that might account for these effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kehry MR. CD40-mediated signalling in B cells. Balancing cell survival, growth, and death. J Immunol 1996; 156: 2345–2348.

    Google Scholar 

  2. Fiumara P, Younes A. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br J Haematol 2001; 113: 265–274.

    Google Scholar 

  3. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997; 9: 330–337.

    Google Scholar 

  4. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers 1999; 14: 135–143.

    Google Scholar 

  5. Klaus GG, Choi MS, Lam EW, Johnson-Leger C, Cliff J. CD40: A pivotal receptor in the determination of life/death decisions in B lymphocytes. Int Rev Immunol 1997; 15: 5–31.

    Google Scholar 

  6. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994; 367: 425–428.

    Google Scholar 

  7. Korthauer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 539–541.

    Google Scholar 

  8. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993; 361: 541–543.

    Google Scholar 

  9. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Longterm human B cell lines dependent on interleukin-4 and antibody to CD40. Science 1991; 251: 70–72.

    Google Scholar 

  10. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993; 177: 1209–1213.

    Google Scholar 

  11. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature 1989; 342: 929–931.

    Google Scholar 

  12. Liu YJ, Cairns JA, Holder MJ, et al. Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B cells: Evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol 1991; 21: 1107–1114.

    Google Scholar 

  13. Holder MJ, Wang H, Milner AE, et al. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction. Eur J Immunol 1993; 23: 2368–2371.

    Google Scholar 

  14. Lomo J, Blomhoff HK, Jacobsen SE, Krajewski S, Reed JC, Smeland EB. Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: Upregulation of Bcl-xL and Mcl-1. Blood 1997; 89: 4415–4424.

    Google Scholar 

  15. Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J Immunol 1995; 155: 3329–3337.

    Google Scholar 

  16. Koopman G, Keehnen RM, Lindhout E, Zhou DF, de Groot C, Pals ST. Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis. Eur J Immunol 1997; 27: 1–7.

    Google Scholar 

  17. Kelly K, Knox KA. Differential regulatory effects of cAMP-elevating agents on human normal and neoplastic B cell functional response following ligation of surface immunoglobulin and CD40. Cell Immunol 1995; 166: 93–102.

    Google Scholar 

  18. Tsubata T, Wu J, Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993; 364: 645–648.

    Google Scholar 

  19. Siebelt F, Berberich I, Shu G, Serfling E, Clark EA. Role for CD40-mediated activation of c-Rel and maintenance of c-myc RNAlevels in mitigating anti-IgM-induced growth arrest. Cell Immunol 1997; 181: 13–22.

    Google Scholar 

  20. Schauer SL, Bellas RE, Sonenshein GE. Dominant signals leading to inhibitor kappaB protein degradation mediate CD40 ligand rescue of WEHI 231 immature B cells from receptormediated apoptosis. J Immunol 1998; 160: 4398–4405.

    Google Scholar 

  21. Padmore L, An S, Gunby RH, Kelly K, Radda GK, Knox KA. CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line. Cell Immunol 1997; 177: 119–128.

    Google Scholar 

  22. Curnock AP, Knox KA. LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells. Cell Immunol 1998; 187: 77–87.

    Google Scholar 

  23. Craxton A, Chuang PI, Shu G, Harlan JM, Clark EA. The CD40-inducible Bcl-2 family member A1 protects B cells from antigen receptor-mediated apoptosis. Cell Immunol 2000; 200: 56–62.

    Google Scholar 

  24. Kuss AW, Knodel M, Berberich-Siebelt F, Lindemann D, Schimpl A, Berberich I. A1 expression is stimulated by CD40 in B cells and rescues WEHI 231 cells from anti-IgM-induced cell death. Eur J Immunol 1999; 29: 3077–3088.

    Google Scholar 

  25. Lin CK, Nguyen TT, Morgan TL, et al. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM. Exp Cell Res 1998; 244: 1–13.

    Google Scholar 

  26. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signalling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96: 9136–9141.

    Google Scholar 

  27. Voorzanger-Rousselot N, Favrot M, Blay JY. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998; 92: 3381–3387.

    Google Scholar 

  28. Johnson PW, Watt SM, Betts DR, et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 1993; 82: 1848–1857.

    Google Scholar 

  29. Ghia P, Boussiotis VA, Schultze JL, et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: Contribution of CD40 signalling in promoting survival. Blood 1998; 91: 244–251.

    Google Scholar 

  30. Andersen NS, Larsen JK, Christiansen J, et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 2000; 96: 2219–2225.

    Google Scholar 

  31. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995–1004.

    Google Scholar 

  32. Heath AW, Chang R, Harada N, et al. Antibodies to murine CD40 stimulate normal B lymphocytes but inhibit proliferation of B lymphoma cells. Cell Immunol 1993; 152: 468–480.

    Google Scholar 

  33. Funakoshi S, Longo DL, Beckwith M, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994; 83: 2787–2794.

    Google Scholar 

  34. Henriquez NV, Floettmann E, Salmon M, Rowe M, Rickinson AB. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. J Immunol 1999; 162: 3298–3307.

    Google Scholar 

  35. Baker MP, Eliopoulos AG, Young LS, Armitage RJ, Gregory CD, Gordon J. Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand. Blood 1998; 92: 2830–2843.

    Google Scholar 

  36. Lefterova P, Marten A, Buttgereit P, et al. Induction of apoptosis in B lymphoma cells by activation with CD40L. Acta Haematol 2000; 103: 168–171.

    Google Scholar 

  37. Szocinski JL, Khaled AR, Hixon J, et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: Induction of bax. Blood 2002; 100: 217–223.

    Google Scholar 

  38. Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res 1996; 56: 1909–1916.

    Google Scholar 

  39. Bergamo A, Bataille R, Pellat-Deceunynck C. CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 1997; 97: 652–655.

    Google Scholar 

  40. Teoh G, Tai YT, Urashima M, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000; 95: 1039–1046.

    Google Scholar 

  41. Hess S, Engelmann H. A novel function of CD40: Induction of cell death in transformed cells. J Exp Med 1996; 183: 159–167.

    Google Scholar 

  42. Eliopoulos AG, Davies C, Knox PG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000; 20: 5503–5515.

    Google Scholar 

  43. von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocytemediated lysis and induces apoptosis. Cancer Res 1999; 59: 1287–1294.

    Google Scholar 

  44. Dotti G, Savoldo B, Takahashi S, et al. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells.Amodel for immunotherapy. Exp Hematol 2001; 29: 952–961.

    Google Scholar 

  45. Alexandroff AB, Jackson AM, Paterson T, et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000; 37: 515–526.

    Google Scholar 

  46. Afford SC, Ahmed-Choudhury J, Randhawa S, et al. CD40 activation-induced, Fas-dependent apoptosis and NFkappaB/AP-1 signalling in human intrahepatic biliary epithelial cells. Faseb J 2001; 15: 2345–2354.

    Google Scholar 

  47. Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: Variable inducibility by cytokines and enhancement of Fasmediated apoptosis. Breast Cancer Res Treat 1998; 50: 27–36.

    Google Scholar 

  48. Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999–3007.

    Google Scholar 

  49. Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001; 7: 691–703.

    Google Scholar 

  50. Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001; 61: 7556–7562.

    Google Scholar 

  51. Yang E, Korsmeyer SJ. Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 1996; 88: 386–401.

    Google Scholar 

  52. Antonsson B, Martinou JC. The Bcl-2 protein family. Exp Cell Res 2000; 256: 50–57.

    Google Scholar 

  53. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59: 1693s–1700s.

    Google Scholar 

  54. MacCarthy-Morrogh L, Mouzakiti A, Townsend P, Brimmell M, Packham G. Bcl-2-related proteins and cancer. Biochem Soc Trans 1999; 27: 785–789.

    Google Scholar 

  55. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–442.

    Google Scholar 

  56. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602–3610.

    Google Scholar 

  57. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–336.

    Google Scholar 

  58. Allsopp TE, Wyatt S, Paterson HF, Davies AM. The proto-oncogene bcl-2 can selectively rescue neurotrophic factordependent neurons from apoptosis. Cell 1993; 73: 295–307.

    Google Scholar 

  59. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998; 281: 1322–1326.

    Google Scholar 

  60. Liu YJ, Mason DY, Johnson GD, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 1991; 21: 1905–1910.

    Google Scholar 

  61. Ning ZQ, Norton JD, Li J, Murphy JJ. Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signalling through CD40 and interleukin-4 receptor: Role for inhibition of an early response gene, Berg36. Eur J Immunol 1996; 26: 2356–2363.

    Google Scholar 

  62. Choi MS, Boise LH, Gottschalk AR, Quintans J, Thompson CB, Klaus GG. The role of bcl-XL in CD40-mediated rescue from anti-mu-induced apoptosis in WEHI-231 B lymphoma cells. Eur J Immunol 1995; 25: 1352–1357.

    Google Scholar 

  63. Zhang X, Li L, Choe J, et al. Up-regulation of Bcl-xL expression protects CD40-activated human B cells from Fas-mediated apoptosis. Cell Immunol 1996; 173: 149–154.

    Google Scholar 

  64. Boise LH, Gonzalez-Garcia M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597–608.

    Google Scholar 

  65. Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993; 151: 1979–1988.

    Google Scholar 

  66. Lin EY, Orlofsky A, Wang HG, Reed JC, Prystowsky MB. A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation. Blood 1996; 87: 983–992.

    Google Scholar 

  67. Choi SS, Park IC, Yun JW, Sung YC, Hong SI, Shin HS. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 1995; 11: 1693–1698.

    Google Scholar 

  68. D'Sa-Eipper C, Subramanian T, Chinnadurai G. bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res 1996; 56: 3879–3882.

    Google Scholar 

  69. D'Sa-Eipper C, Chinnadurai G. Functional dissection of Bfl-1, a Bcl-2 homolog: Anti-apoptosis, oncogene-cooperation and cell proliferation activities. Oncogene 1998; 16: 3105–3114.

    Google Scholar 

  70. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 1993; 90: 3516–3520.

    Google Scholar 

  71. Reynolds JE, Yang T, Qian L, et al. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994; 54: 6348–6352.

    Google Scholar 

  72. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89: 630–643.

    Google Scholar 

  73. Zhou P, Levy NB, Xie H, et al. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 2001; 97: 3902–3909.

    Google Scholar 

  74. Lomo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res 1996; 56: 40–43.

    Google Scholar 

  75. Opipari AW, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267: 12424–12427.

    Google Scholar 

  76. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996; 70: 8653–8659.

    Google Scholar 

  77. Sarma V, Lin Z, Clark L, et al. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995; 270: 12343–12346.

    Google Scholar 

  78. Jaattela M. Escaping cell death: Survival proteins in cancer. Exp Cell Res 1999; 248: 30–43.

    Google Scholar 

  79. Guo M, Hay BA. Cell proliferation and apoptosis. Curr Opin Cell Biol 1999; 11: 745–752.

    Google Scholar 

  80. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777–2783.

    Google Scholar 

  81. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917–921.

    Google Scholar 

  82. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111: 196–203.

    Google Scholar 

  83. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921–1925.

    Google Scholar 

  84. Taylor ST, Hickman JA, Dive C. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors. J Natl Cancer Inst 2000; 92: 18–23.

    Google Scholar 

  85. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: A role for TNF-R1 activation by endogenous membrane-anchored TNF. Embo J 1999; 18: 3034–3043.

    Google Scholar 

  86. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 1995; 182: 1265–1273.

    Google Scholar 

  87. Schattner E, Friedman SM, Garrone P, et al. Fas expression and apoptosis in human B cells. Immunol Res 1996; 15: 246–257.

    Google Scholar 

  88. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000; 96: 2917–2924.

    Google Scholar 

  89. Wang D, Freeman GJ, Levine H, et al. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 1997; 97: 409–417.

    Google Scholar 

  90. Plumas J, Jacob MC, Chaperot L, et al. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998; 91: 2875–2885.

    Google Scholar 

  91. Yamada M, Shiroko T, Kawaguchi Y, et al. CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors. Int J Cancer 2001; 92: 589–599.

    Google Scholar 

  92. van Eijk M, Medema JP, de Groot C, et al. Cutting edge: Cellular Fas-associated death domain-like IL-1-converting enzyme-inhibitory protein protects germinal center B cells from apoptosis during germinal center reactions. J Immunol 2001; 166: 6473–6476.

    Google Scholar 

  93. Hennino A, Berard M, Casamayor-Palleja M, et al. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J Immunol 2000; 165: 3023–3030.

    Google Scholar 

  94. Hennino A, Berard M, Krammer PH, et al. FLICE-inhibitory protein is a key regulator of germinal center B cell apoptosis. J Exp Med 2001; 193: 447–458.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research UK Oncology Unit, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK

    C. Dallman, P. W. M. Johnson & G. Packham

Authors
  1. C. Dallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. W. M. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Packham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Packham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dallman, C., Johnson, P.W.M. & Packham, G. Differential regulation of cell survival by CD40. Apoptosis 8, 45–53 (2003). https://doi.org/10.1023/A:1021696902187

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021696902187

Search

Navigation